Shared on16 Aug 25Fair value Decreased 18%
agilon health’s consensus price target has been revised downward, primarily reflecting declines in its future P/E ratio and slightly lower net profit margin, with fair value now set at $1.74. What's in the News The Board amended and restated the by-laws to refine officer roles and align with updates in Delaware law.
Shared on01 Aug 25Fair value Decreased 44%
agilon health's consensus analyst price target has been downwardly revised as reduced future P/E expectations outweigh a modest improvement in net profit margin, resulting in a new fair value of $3.59. What's in the News Published peer-reviewed study found that, within agilon's value-based care (VBC) model, patients managed by women primary care physicians had equal or better clinical outcomes, lower healthcare utilization, and higher revenues per patient compared to those managed by men.
Shared on09 Apr 25Fair value Increased 9.14%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 1.69%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 13%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.